Pub Date : 2021-01-01DOI: 10.12206/j.issn.1006-0111.202011002
何盈盈 唐庆龙 李康 顾妍秋 陈啸飞 曾垣烨
The outbreak of COVID-19 posed a huge threat to human health and social stability. With the rapid spread of the virus around the world, the drug development and related research of novel coronavirus (SARS-CoV-2) have become an urgent issue in the medical field. COVID-19 fails into the category of epidemics in the theory of TCM. LHQW capsule has repeatedly played an important role in many major epidemics. Previous studies have shown that LHQW capsule can inhibit the biological activity of varied viruses including MERS-CoV and SARS-CoV. The paper summarizes the relevant research data and achievements of LHQW capsule in the past few years, reviews the chemical constituents, clinical efficacy and pharmacological effects of LHQW capsule, and provides scientific basis for the anti-virus mechanism of LHQW capsule and clinical treatment of COVID-19. (English) [ABSTRACT FROM AUTHOR] 新型冠状病毒肺炎（COVID-19）疫情的爆发对人类健康与社会稳定造成了巨大威胁。随着病毒在全球迅速蔓 延，针对新型冠状病毒（SARS-CoV-2）的药物开发及其相关研究成为医学领域的迫切问题。COVID-19 归入中医学理论中的 疫病范畴，连花清瘟胶囊（颗粒）屡次在重大疫情中发挥重要作用。既往研究表明，连花清瘟胶囊可能抑制 MERS-CoV、 SARS-CoV 等多种病毒的生物活性。该文整理了历年国内外有关连花清瘟胶囊相关研究成果，从其化学成分、临床功效以 及药理作用等方面进行综述分析，以期对连花清瘟胶囊抗病毒机制研究和新冠肺炎临床治疗提供科学依据。 (Chinese) [ABSTRACT FROM AUTHOR] Copyright of Journal of Pharmaceutical Practice is the property of Journal of Pharmaceutical Practice Editorial Department and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
{"title":"Research progress on chemical composition and clinical efficacy of Lianhua Qingwen (LHQW) capsule, a traditional Chinese medicine (TCM) used to treat COVID-19","authors":"何盈盈 唐庆龙 李康 顾妍秋 陈啸飞 曾垣烨","doi":"10.12206/j.issn.1006-0111.202011002","DOIUrl":"https://doi.org/10.12206/j.issn.1006-0111.202011002","url":null,"abstract":"The outbreak of COVID-19 posed a huge threat to human health and social stability. With the rapid spread of the virus around the world, the drug development and related research of novel coronavirus (SARS-CoV-2) have become an urgent issue in the medical field. COVID-19 fails into the category of epidemics in the theory of TCM. LHQW capsule has repeatedly played an important role in many major epidemics. Previous studies have shown that LHQW capsule can inhibit the biological activity of varied viruses including MERS-CoV and SARS-CoV. The paper summarizes the relevant research data and achievements of LHQW capsule in the past few years, reviews the chemical constituents, clinical efficacy and pharmacological effects of LHQW capsule, and provides scientific basis for the anti-virus mechanism of LHQW capsule and clinical treatment of COVID-19. (English) [ABSTRACT FROM AUTHOR] 新型冠状病毒肺炎（COVID-19）疫情的爆发对人类健康与社会稳定造成了巨大威胁。随着病毒在全球迅速蔓 延，针对新型冠状病毒（SARS-CoV-2）的药物开发及其相关研究成为医学领域的迫切问题。COVID-19 归入中医学理论中的 疫病范畴，连花清瘟胶囊（颗粒）屡次在重大疫情中发挥重要作用。既往研究表明，连花清瘟胶囊可能抑制 MERS-CoV、 SARS-CoV 等多种病毒的生物活性。该文整理了历年国内外有关连花清瘟胶囊相关研究成果，从其化学成分、临床功效以 及药理作用等方面进行综述分析，以期对连花清瘟胶囊抗病毒机制研究和新冠肺炎临床治疗提供科学依据。 (Chinese) [ABSTRACT FROM AUTHOR] Copyright of Journal of Pharmaceutical Practice is the property of Journal of Pharmaceutical Practice Editorial Department and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)","PeriodicalId":22870,"journal":{"name":"The Journal of Pharmaceutical Practice","volume":"43 1","pages":"291-361"},"PeriodicalIF":0.0,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"84985020","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2020-05-01DOI: 10.12206/J.ISSN.1006-0111.202003163
Cai Mengcheng, Yuan Chaoqin
Objective To explore the molecular targets and related potential pathways of Jinzhen oral liquid in the treatment of coronavirus disease 2019 (COVID-19). Methods The potential blood-entry active ingredients and targets of Jinzhen oral liquid were retrieved by Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP). COVID-19 related gene targets were retrieved through GeneCard. Protein-protein interaction network of common targets was constructed by String. Gene Ontology, Kyoto Encyclopedia of Genes and Genomes pathway analysis of the intersection network were conducted by Bioconductor Database. Results 141 active ingredients were screened according to oral bioavailability and drug similarity. 350 target genes directly related to COVID-19 were obtained from the GeneCard. 47 genes were obtained from the intersection of component-target and disease-target. These genes were mainly involved in response to lipopolysaccharide, oxidative stress and other biological processes. Molecular functions were mainly related to cytokine receptor binding, cytokine activity, receptor ligand activity, etc. The active ingredients were related to IL-17 signaling pathway, TNF and Influenza A signaling pathway, etc. Conclusion The possible active compounds of Jinzhen oral liquid could be anti-viral and anti-inflammatory that could have potential therapeutic effect against virus infection, lung injury and inflammation caused by SARS-CoV-2.
{"title":"Mechanism of Jinzhen oral liquid in treatment of coronavirus disease 2019 based on network pharmacology/ 药学实践杂志","authors":"Cai Mengcheng, Yuan Chaoqin","doi":"10.12206/J.ISSN.1006-0111.202003163","DOIUrl":"https://doi.org/10.12206/J.ISSN.1006-0111.202003163","url":null,"abstract":"Objective To explore the molecular targets and related potential pathways of Jinzhen oral liquid in the treatment of coronavirus disease 2019 (COVID-19). Methods The potential blood-entry active ingredients and targets of Jinzhen oral liquid were retrieved by Traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP). COVID-19 related gene targets were retrieved through GeneCard. Protein-protein interaction network of common targets was constructed by String. Gene Ontology, Kyoto Encyclopedia of Genes and Genomes pathway analysis of the intersection network were conducted by Bioconductor Database. Results 141 active ingredients were screened according to oral bioavailability and drug similarity. 350 target genes directly related to COVID-19 were obtained from the GeneCard. 47 genes were obtained from the intersection of component-target and disease-target. These genes were mainly involved in response to lipopolysaccharide, oxidative stress and other biological processes. Molecular functions were mainly related to cytokine receptor binding, cytokine activity, receptor ligand activity, etc. The active ingredients were related to IL-17 signaling pathway, TNF and Influenza A signaling pathway, etc. Conclusion The possible active compounds of Jinzhen oral liquid could be anti-viral and anti-inflammatory that could have potential therapeutic effect against virus infection, lung injury and inflammation caused by SARS-CoV-2.","PeriodicalId":22870,"journal":{"name":"The Journal of Pharmaceutical Practice","volume":"63 1","pages":"193-201"},"PeriodicalIF":0.0,"publicationDate":"2020-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81364764","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：